Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients.
about
Optimizing treatment success in multiple sclerosisMultiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approachRationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.A computer-based screening method for distress in patients with multiple sclerosis: a feasibility studyThe PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimodDesigning an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System.New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.The importance of collecting structured clinical information on multiple sclerosis.Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.[Real-world evidence : Benefits and limitations in multiple sclerosis research].
P2860
Q26771968-E6E572AD-AF30-438A-AFC9-54C93D111E40Q28080043-9B8D1B86-C2C8-44DC-9F36-FD2C948D38F0Q31115496-1970E121-8CC9-4178-AB34-F124878718F3Q33642908-6B3A2405-5EFC-4A77-A994-D459F6A9240EQ33807826-BE23C896-ED65-4A18-9FAA-AA5825C5FFE5Q35666531-B5C82D26-4BE7-4A3C-BFC2-FCAB169D98A0Q36073992-2777A51A-54D1-4484-9BB8-ECC714F6CAAAQ36097847-4BA4C11D-0339-4198-BB11-9B6ED340D8E3Q36492533-0D003AE6-10A4-4DF8-8978-48CB19458685Q37045253-F1A66C2D-B41F-443E-81B2-0132C43A201CQ42361890-C17599EA-DE11-48CC-8F9A-07830676487DQ42747344-4E3ED1DB-0E0E-4CE3-A5D8-AE8FBCEE4C90Q47255582-FA751817-7BC3-47AA-A3A7-6B088BFA1EB8Q54304253-5C16C53F-B2DB-4F50-897E-CCE5697346F1
P2860
Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Multiple sclerosis documentati ...... to management of MS patients.
@en
type
label
Multiple sclerosis documentati ...... to management of MS patients.
@en
prefLabel
Multiple sclerosis documentati ...... to management of MS patients.
@en
P2093
P2860
P1476
Multiple sclerosis documentati ...... to management of MS patients.
@en
P2093
Alexander Suhrbier
Katja Thomas
Lars Großmann
Marco Eulitz
Raimar Kempcke
Thorsten Schultheiss
P2860
P2888
P356
10.1007/S00702-013-1041-X
P478
120 Suppl 1
P577
2013-06-01T00:00:00Z